DavidPerlmutterMD · 2026-01-20 · David Perlmutter (host), Elizabeth Parrish
Is Aging a Disease? Inside the First Human Gene Therapy Experiment | Elizabeth Parrish
31 research-tied claims examined: 3 contradicted 4 overstated 4 context 13 supported 7 unverified
3 Contradicted by research
Prior to 1960, the US government did not consider cancer a disease, but regarded it as a consequence of aging.
"And this takes us back to 1960 when we finally encouraged the US government to consider cancer a disease. As you know, it wasn't considered a disease. It was considered a consequence of aging." (said at 0:07:01)
Historical and legislative records contradict the claim that the US government did not consider cancer a disease until 1960. The US federal government formally recognized cancer as a disease and a major public health priority decades earlier. In 1937, President Franklin D. Roosevelt signed the National Cancer Institute Act into law, creating the National Cancer Institute (NCI) within the Public Health Service to conduct and support research into the causes, diagnosis, and treatment of cancer. Furthermore, in 1955, the federal government established the Cancer Chemotherapy National Service Center to organize a national effort for developing cancer therapeutics.
- contradicts: A History of Cancer Chemotherapy (Cancer Research 2008) · cited 1966x in the literature
"It was, however, four World War II-related programs, and the effects of drugs that evolved from them, that provided the impetus to establish in 1955 the national drug development effort known as the Cancer Chemotherapy National Service Center." (abstract, passage verified)
openalexfull study (doi) - contradicts: How, After a Decade of Public & Private Wrangling, FDR Signed NCI into Law in 1937 (Oncology Times 2006) · cited 1x in the literature
"On August 5, 1937, President Franklin Delano Roosevelt signed into law the National Cancer Institute Act, and two months later ground was broken for the NCI building." (abstract, passage verified)
openalexfull study (doi)
PGC-1alpha promotes mitochondrial biogenesis and enhances cellular energy metabolism across the body, including in microglial cells.
"And so PGC-1alpha is a gene therapy that targets mitochondrial biogenesis, the growth of new mitochondria, and fosters better energy, metabolism, utilization on the part of cells throughout the body, including the brain's immune cells, the microglial cells." (said at 0:33:32)
The claim bundles two distinct assertions: one regarding the identity of PGC-1α and one regarding its biological function.
1. Calling PGC-1α a "gene therapy" is factually incorrect. PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is an endogenous transcriptional coactivator protein encoded by the human PPARGC1A gene, not a therapy itself (though experimental gene delivery systems targeting or delivering PGC-1α exist in preclinical research).
2. The statement that PGC-1α promotes mitochondrial biogenesis and enhances cellular energy metabolism across body tissues, including in brain microglial cells, is biologically accurate and supported by evidence.
Evaluating the exact spoken sentence according to the least accurate bundled assertion, the claim is contradicted due to mischaracterizing an endogenous regulatory protein as a gene therapy.
- supports: Microglial PGC-1α protects against ischemic brain injury by suppressing neuroinflammation. (Genome medicine 2021) · cited 207x in the literature
"PPARγ coactivator-1α (PGC-1α), as a master coregulator of gene expression in mitochondrial biogenesis, was found to be transiently upregulated in microglia after AIS." (abstract, passage verified)
pubmedfull study (doi) - contradicts: Covering the Role of PGC-1α in the Nervous System. (Cells 2021) · cited 39x in the literature
"The peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a well-known transcriptional coactivator involved in mitochondrial biogenesis." (abstract, passage verified)
pubmedfull study (doi) - supports: The Role of PGC-1α in Neurodegenerative Diseases: Molecular Mechanisms, Translational Chal… (Molecular neurobiology 2026) · cited 1x in the literature
"Current findings indicate that PGC-1α supports mitochondrial biogenesis, oxidative phosphorylation, antioxidant defense, mitophagy, autophagy, protein quality control, and inflammatory balance." (abstract, passage verified)
pubmedfull study (doi)
A double-blind, placebo-controlled trial conducted at the University of South Florida movement disorder clinic demonstrated that glutathione treatment is highly effective for Parkinson's disease.
"The comment was, "Well, you know, you really need to do a double-blind, double-blind placebo-controlled trial and publish it in a peer-reviewed journal." And I thought, "It's working. Why do I need to do that?" Okay, we'll do it. We did do it. And we did it at University of South Florida in the movement disorder clinic and it proved incredibly effective." (said at 0:55:13)
The double-blind, placebo-controlled trial conducted at the University of South Florida Movement Disorder Center evaluating intravenous glutathione for Parkinson's disease (Hauser et al., 2009) did not find that glutathione was highly effective. In 21 participants randomized to intravenous glutathione (1,400 mg three times weekly for 4 weeks) or placebo, there were no statistically significant differences in Unified Parkinson's Disease Rating Scale (UPDRS) scores between groups (P = 0.32), and the authors concluded only that glutathione was well tolerated with preliminary data suggesting a possible mild symptomatic effect warranting larger studies.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.